Status:
COMPLETED
Natural Disease Progression in Participants With Choroideremia
Lead Sponsor:
Biogen
Conditions:
Choroideremia
Eligibility:
All Genders
10+ years
Brief Summary
The primary objective of this study is to quantify disease progression measured by best corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM) participants. The secondary o...
Detailed Description
This study is a retrospective cohort study of CHM eyes and participants which will include all eligible participants and eyes with the first documented diagnosis of CHM from July 1st, 2013 to December...
Eligibility Criteria
Inclusion
- Key
- Cohort 1: All CHM Participants
- Participants with a documented diagnosis of CHM identified by the presence of International Classification of Diseases (ICD)-9/10 or SNOMED coding:
- ICD-9: 363.55
- ICD-10: H31.2
- SNOMED-CT: 75241009
- Cohort 2: Trial-Matched CHM Participants
- Male participants with a documented diagnosis of CHM identified by the presence of ICD-9/10 or SNOMED coding:
- ICD-9: 363.55
- ICD-10: H31.21
- SNOMED-CT: 75241009
- Key
Exclusion
- N/A
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
August 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 10 2021
Estimated Enrollment :
1178 Patients enrolled
Trial Details
Trial ID
NCT04795206
Start Date
August 26 2020
End Date
August 10 2021
Last Update
September 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
San Francisco, California, United States, 94107